NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO.,LTD. Funds and ETFs Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
Equities
603707
CNE100002WP3
Pharmaceuticals
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.03 CNY | -1.59% |
|
+6.98% | -13.13% |
ETFs positioned on Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.49% | 2 M€ | -14.86% | - | |
| 0.00% | 2,808 M€ | +6.68% | - | |
| 0.00% | 441 M€ | +4.60% | - | |
| 0.00% | 149 M€ | +2.17% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 34 M€ | +2.43% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 15 M€ | +11.24% |
Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of heparin-related products. The Company's main products include standard heparin raw materials, low molecular weight heparin raw materials and their preparations, such as heparin sodium raw materials, heparin sodium, enoxaparin sodium injection, dalteparin sodium injection and Naqu Heparin Calcium Injection. The Company mainly exports its products to the United States and European countries.
Sector
Pharmaceuticals
Calendar
31/07/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
13.03
CNY
Average target price
20.18
CNY
Spread / Average Target
+54.91%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -13.13% | 2.94B | |
| +26.32% | 661B | |
| +26.74% | 566B | |
| -6.46% | 352B | |
| +18.81% | 332B | |
| +3.85% | 283B | |
| +13.43% | 231B | |
| +4.71% | 200B | |
| -9.53% | 195B | |
| -4.10% | 145B |
- Stock Market
- Equities
- 603707 Stock
- Funds and ETFs Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd.
